Main Article Content


Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level's targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients' ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.


Filgrastim absolute neutrophyl count (ANC) acute leukemia chemotherapy induce neutropenia (CIN)

Article Details

How to Cite
Widya, R. A., Nugroho, S., Winarsih, S., & Yulistiani, Y. (2019). Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia. Folia Medica Indonesiana, 55(1), 10–16.


  1. Bekkering S, Torensma R (2013). another look at the life of a neutrophil. World Journal of Hematology 2, 44-58
  2. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014). Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, A Review. Cell Death and Differentiation 21, 15-25
  3. Crawford J, Caserta C, Rolla F (2010). Hematopoietic growth factors: ESMO clinical practice guideline for the applications. Annals of Oncology 21, 248-51
  4. Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H (2005). Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: Exploration of risk factors for febrile neutropenia. Supprotive Cancer Therapy 3, 36-46
  5. Dalal S, Zhukovsky DS (2006). Pathophysiology and management of fever. Journal of Supportive Oncology 4, 9-16
  6. Dale DC, Quinton LJ, Nelson S (2013). Colony-stimulating factors for prevention and treatment of neutropenia and infection diseases. In: The neutrophils new outlook for old cells. 3rd Ed. US, Imperial College Press, p 399-417
  7. Ghalaut PS, Sen R, Dixit G (2008). Role of Granulocyte Colony Stimulating Factor (G-CSF) in chemotherapy induced neutropenia. Journal Association Of Physicians India 56, 942-44
  8. Hansen Molgaard L, Mottonen M, Glosli H, Jonmundsson GK, Abrahamsson J, Hasle H (2010). Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. British Journal of Haematology 151, 447-59
  9. Holland SM, Gallin JI (2015). Disorder of granulocytes and monocytes, In: Harrison's Principles of Internal Medicine. 19th ed. US, McGraw-Hill Companies, Inc, p. 413-423
  10. Lyman GH, Abella E, Pettengell R (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology 90, 190-199
  11. Lyman GH, Dale DC, Culakova E, Poniewuerski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013). The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Annals of Oncology. Oxford University Press on behalf of the European Society for Medical Oncology 00, 1-10
  12. Mehta AB, Hoffbrand AV (2014). Haemopoiesis: physiology and pathology, In: Haematology at a Glance. 4th Ed. UK, Wiley Blackwell, p 10-13
  13. Mitchell S, Li Xiaoyan, Woods Matthew, Garcia J, Massey Hebard K, Barron R, Samuel M (2016). Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. Journal of Oncology Pharmacy Practice. SagePub UK 0, 1-15
  14. Molineux G (2011). Granulocyte colony-stimulating factors, In Lyman GH, Dale DC Hematopoietic Growth Factors in Oncology vol. 157. New York, Springer, p 33-54
  15. Neumann TA, Foote M (2012). The safety profile of filgrastim and pegfilgrastim In: Twety years of G-CSF, milestone in drug therapy. Springer, p 395-408
  16. Permono B, Sutaryo, Ugreseno IDG, Windiastuti E, Abdulsalam M (2010). Leukemia akut, In: Buku ajar hematologi-onkologi anak cetakan ketiga. Badan Penerbit Ikatan Dokter Anak Indonesia, p 236-47
  17. Pertiwi NMI, Niruri R, Ariawati K (2013). Gangguan hematologi akibat kemoterapi pada anak dengan leukemia limfositik akut di Rumah Sakit Umum Pusat Sanglah. Jurnal Farmasi Udayana, 59-61
  18. Rodriguez ZN, Tordecilla CJ, Campbell BM, Joannon SP, Rizzardini LC, Soto AV, Verdugo LP (2005). Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia. Revista Chilena de Infectologia 22, 223-27
  19. Rosary HAS (2010). Penggunaan granulocyte colony stimulating factor pada pasien tumor padat yang mengalami neutropenia. Sari Pediatri 11, 428-33
  20. Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M (2012). Pharmacokonetic and -dynamic Modelling of G-CSF Derivates in Humans. Theoretical Biology and Medical Modelling, BioMed Central 9 Suppl 32, 1-28
  21. Sieff CA (2016). Regulation of Myelopoiesis. UpToDate Wolter Kluwer, 1-35
  22. Sudewi N, Alan R, Endang W (2007). Kejadian demam neutropenia pada keganasan. Sari Pediatri 8, S68-72
  23. Tubergen DG, Bleyer A, Ritchey AK, Friehling E (2016). The Leukemias In: Kliegman RM, Stanton BF, St. Geme III JW, Schor NF. Nelson Textbook of Pediatrics. 20th Ed. Canada, Elsevier, Inc, p 2437-44
  24. UpToDate (2016). Filgastrim: Pediatric Drug Information. UpToDate. Wolters Kluwer, 1-9
  25. Velasco RP (2010). Review of granulocyte-stimulating factors in the treatment of established febrile nuetropenia. Journal of Oncology Pharmacy Practice 17, 225-32
  26. Welte K (2012). Discovery of G-CSF and early clinical studies. In: G. Molineux, Foote M., Arvedson, E., (eds). Twenty Years of G-CSF Clinical and Nonclinical Discoveries, Milestones in Drug Therapy. Mirogojska, University Hospital for Infectious Disease "Dr. Fran Mihaljevic”, p 15-24